KCT0009187已完成Unknown
A 12 Week, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of NVP-2106 on improvement of Cognitive Function
VP Healthcare0 个研究点目标入组 120 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 60(Year) 至 74(Year)（—）
- 性别
- All
入选标准
- •1) Adult men and women who are 60 years of age or older at the time of screening and complain of memory decline
- •2) Those whose CERAD-K word list memory/recall/recognition test score decreased by 1-2 SD from the normal value (those who satisfy at least 1 of the 3 items above)
- •3) Those with a total score of 22 or less on the Korean version of the Montreal Cognitive Assessment (MOCA-K)
- •4) A person who, after hearing and fully understanding the detailed explanation of this human application test, voluntarily decides to participate and agrees in writing to comply with the precautions
排除标准
- •1) Those who are currently treated with DSM-IV Axis I Disorders in Structured Clinical Interview for DSM-IV (SCID) conducted at the time of the screening test or have a history of being treated within the last three years.
- •2) A person who has continuously consumed lactobacillus formulation (or probiotic formulation) and fermented dairy products (yogurt, cheese, etc.) within 2 weeks prior to the screening test (four times or more/week).
- •3) A person who has alcohol abuse or dependence within three months prior to a screening test.
- •4) Those with clinically significant acute or chronic cardiovascular system, endocrine system, immune system, respiratory system, hepatometer, kidney and urinary system, neuropsychiatric system, musculoskeletal system, inflammatory and blood and oncogenic, gastrointestinal disease, etc. that require treatment.
- •5) A person who has taken drugs, health functional foods or herbal medicines related to cognitive and memory improvement within one month prior to a screening test (see prohibited drugs).
- •6) A person who has taken psychiatric drugs such as antipsychotic drugs, antidepressants, mood control agents, sleeping pills, and anti-anxiety drugs within one month prior to a screening test.
- •7) Those who have taken antibiotics within four weeks prior to a screening test.
- •8) A person who has donated whole blood within one month before the screening test or donated ingredients within two weeks.
- •9) A person who has participated in another human body application test within three months prior to the screening test.
- •10) Those who show the following results in diagnostic tests and medical tests.
- •? AST, ALT > 3 times the upper limit of the reference range
- •? Serum Creatinine > 2.0 mg/dL
- •11) A person who determines that the examiner is unfit to participate in the study due to other reasons, including the results of diagnostic tests and medical tests.
研究者
相似试验
招募中
不适用
A 12 week, Randomized, Double-blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of EDL on DyspepsiaDiseases of the digestive systemKCT0005229ovaKmed100
已完成
不适用
Placebo-Controlled Clinical Trial of Efficacy and Safety of MC01 on the Skin Wrinkle Improvement and MoisturizingDiseases of the skin and subcutaneous tissueKCT0007499Maeil Health Nutrition100
进行中（未招募）
不适用
Clinical Trial for the Evaluation of the Efficacy and Safety of L. curvatus HY7601 and L. plantarum KY1032 on Reducing body weight and body fat on Overweight or Obesity subjectsEndocrine, nutritional and metabolic diseasesKCT0007117Vievis NAMUH Hospital72
尚未招募
不适用
a clinical trial to effect of oral lacto-bacteria for the improvement of periodontal diseaseKCT0006582DENTIS63
Unknown
2 期
Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset SeizuresCTRI/2010/091/001332ovartis Health care Private Limited57